Component
Steady-state nevirapine AUC, Cmax and 12-hour concentration
Species, preparation, dose and limitations are retained on linked claims.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.
Experimental context and source evidence
- dose
- Nevirapine alone then with 1.85 g/day Moringa leaf powder
- duration
- 14 days coadministration
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Adults with HIV receiving steady-state nevirapine
- limitations
- The small one-sequence study supports a null at this product and dose, not absence of interaction with every drug or preparation.
- nutrient_topic
- Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
- organism
- Adults with HIV receiving steady-state nevirapine
- plain_language
- In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration.
- primary_references
- Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. (2017). https://pubmed.ncbi.nlm.nih.gov/28293270/ DOI: 10.1186/s12981-017-0140-4
- route
- Oral
- tissue
- Intensive 12-hour nevirapine pharmacokinetics
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 178–187
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Adults with HIV receiving steady-state nevirapine · source_derived_draft · unverified_draft
## moringa-nevirapine-pk-null In eleven evaluable adults with HIV, 1.85 g/day Moringa leaf powder for 14 days did not significantly alter steady-state nevirapine AUC, Cmax or 12-hour concentration. Model/species: Adults with HIV receiving steady-state nevirapine Tissue/system: Intensive 12-hour nevirapine pharmacokinetics Exposure: Nevirapine alone then with 1.85 g/day Moringa leaf powder Route: Oral Duration: 14 days coadministration Limits: The small one-sequence study supports a null at this product and dose, not absence of interaction with every drug or preparation. Primary reference: Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over study. (2017). https://pubmed.ncbi.nlm.nih.gov/28293270/ DOI: 10.1186/s12981-017-0140-4 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.